Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Aurobindo Pharma Business Update

Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.

Source

NSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Aurobindo Pharma Ltd: key numbers

Share price
₹1,644.80
Market cap
₹95,530 Cr
Revenue (annual)
₹33,653 Cr
Net profit (annual)
₹3,505 Cr
P/E (TTM)
24.2×Sector 46.1×
Promoter holding
51.88%+0.00% QoQ
FII holding
17.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Aurobindo Pharma Ltd

All →

Other business update announcements

All →